key: cord-0806256-i204ahxj
authors: Rappaport, Stephen H.; Clark, Jenna M.; Delibert, Samantha; Maynard, Kaylee M.; Prasad, Paritosh; Kaufman, David C.; Pietropaoli, Anthony P.; Quill, Caroline M.; Groth, Christine M.
title: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
date: 2020-12-15
journal: Am J Respir Crit Care Med
DOI: 10.1164/rccm.202006-2511le
sha: 0286565e6f6e063f545d1e19445bd2fd88416855
doc_id: 806256
cord_uid: i204ahxj

nan

To the Editor:

We read with interest the article by Dutt and colleagues describing measurement of anti-factor Xa (FXa) activity in ward patients with coronavirus disease (COVID-19) as well as those requiring intensive care (1) . The authors suggest that patients admitted to an ICU with COVID-19 may warrant a higher starting dose of pharmacological thromboprophylaxis, although the optimal dose in these patients is uncertain pending upcoming randomized controlled trials. Current guidelines from various medical societies suggest routine pharmacological thromboprophylaxis in patients with COVID-19. However, there is a lack of consensus on whether standard-dose or higher intermediate-dose thromboprophylaxis should be used (2) (3) (4) (5) . We would like to present our experience with measuring anti-FXa activity using a higher, weight-based dose of enoxaparin for thromboprophylaxis. This retrospective observational study was deemed exempt by our institutional review board.

In early April, we noticed a high rate of thrombosis and thromboembolism among critically ill patients with COVID-19, an observation consistent with those in other institutions (6) (7) (8) . Therefore, we adopted intermediate-dose thromboprophylaxis for critically ill patients with COVID-19 with enoxaparin (0.5 mg/kg twice daily), as described in Table 1 , as our new standard of care. The dosages were selected based on several single-center studies suggesting higher rates of attainment of target anti-FXa activity with higher-dose enoxaparin (9, 10) . Importantly, the target anti-FXa activity for pharmacologic prophylaxis is not evidence based, and adjusting doses to provide higher attainment of target activity was not demonstrated to improve clinical outcomes.

We monitored anti-FXa activity for the first 40 patients receiving this dosing strategy. Anti-FXa was checked 3-4 hours after the third or fourth dose of the intermediate-dose enoxaparin regimen. The enoxaparin dose was then adjusted as necessary to achieve a target anti-FXa activity of 0.2-0.5 U/ml.

Results are shown in Table 2 . Seventy-five percent (n = 33) of patients achieved the targeted anti-FXa activity without further dose adjustment. Twenty-five percent (n = 11) of patients had their dose adjusted from institutional guideline recommended doses at some point in their hospitalization. Only three patients had dose adjustment because of their anti-FXa activity, with decreased dosage for two patients, one of whom later developed venous thromboembolism. Only two patients had enoxaparin decreased or stopped because of bleeding (hematuria in both cases). Four patients had their dosages increased to a therapeutic regimen because of clinically suspected (n = 2) or confirmed (n = 2) clotting events. Both patients with confirmed clotting events and one patient with a suspected clotting event were initially on standard-dose thromboprophylaxis before the institutional transition to intermediate-dose thromboprophylaxis.

We achieved a high rate of the targeted anti-FXa activity using this intermediate dosing scheme. Most patients outside the target anti-FXa range were above rather than below goal concentrations. After reviewing this data, our institution decided to continue intermediate-dose thromboprophylaxis but eliminate routine anti-FXa monitoring because it rarely resulted in dose adjustments. Only 2 of the 10 patients with anti-FXa activity of greater than 0.5 U/ml were decreased because of this monitoring, which was likely due to concern over the high rates of thromboembolic complications in this population. In addition, anti-FXa monitoring for thromboprophylaxis is controversial, especially in intensive care (11) (12) (13) . There is no clear relationship between anti-FXa activity and the safety or efficacy of thromboprophylaxis. Although low anti-FXa activity has been associated with thromboembolism, there is no proven benefit to adjusting the enoxaparin dose to a "target" anti-FXa activity. Furthermore, the target anti-FXa activity of 0.2-0.5 U/ml has not been rigorously validated.

In Maximum initial enoxaparin dose = 100 mg, subcutaneously, q12h. Target peak anti-FXa 0.2-0.5 U/ml; draw 3-4 hours after third or fourth dose of regimen. If anti-FXa , 0.2 U/ml, increase dose to next syringe size and keep current frequency. If anti-FXa . 0.5 U/ml, decrease dose to next syringe size or consider package labeled prophylaxis dosing.

Thromboprophylaxis in COVID-19: anti-FXa-the missing factor?

Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines

COVID-19) treatment guidelines. Bethesda, MD: National Institutes of Health

Routine venous thromboembolism prophylaxis may Be inadequate in the hypercoagulable state of severe coronavirus disease 2019

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

COVID-19 update: covid-19-associated coagulopathy

If some is good, more is better: an enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis

Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient

Anti-Xa assays: what is their role today in antithrombotic therapy?

The anti-factor xa range for low molecular weight heparin thromboprophylaxis

Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review

Author disclosures are available with the text of this letter at

Reply to Rappaport et al.

We read with interest the communication from Rappaport and colleagues describing their experience measuring anti-factor Xa (FXa) activity in critically unwell patients with coronavirus disease (COVID-19) infection, receiving intermediate-dose thromboprophylaxis with enoxaparin (0.5 mg/kg twice daily) as standard care. The authors conclude that their results suggest anti-FXa monitoring is not required for critically unwell patients receiving an escalated regime of thromboprophylaxis.The authors measured anti-FXa activity in 40 critically unwell patients within 48 hours of admission and reported the need for dose adjustment thereafter to obtain a target anti-FXa activity of 0.2-0.5 U/ml. Seventy-five percent of patients achieved the target anti-FXa range with no further dose adjustment.This contrasts with our own report (1), in which only 5% of intensive treatment unit patients (majority intubated) managed using a standard thromboprophylaxis regime (40 mg enoxaparin once daily) achieved target anti-FXa activity (0.2-0.4 U/ml). The authors did not define "critically unwell patients" as those requiring mechanical ventilation; however, these reports together provide support for more intensive thromboprophylaxis regimes for patients with severe COVID-19 infection admitted to the intensive treatment unit.As highlighted in our research correspondence, we agree that uncertainty remains about the value of anti-FXa monitoring in patients receiving thromboprophylaxis with low molecular heparin (2) . Nevertheless, in the absence of clinical trial data confirming an optimal anticoagulation strategy for a condition with a recognized spectrum of thrombosis and clinically relevant bleeding (3, 4), we suggest that the use of anti-FXa activity to inform dosing should not be completely dismissed.Patients with COVID-19 demonstrate dynamic flux in their clinical progress accompanied by underlying changes in their inflammatory and coagulopathic state (5). Such fluctuations may influence heparin resistance and low-molecular weight heparin clearance. It is unclear whether Rappaport and colleagues measured anti-FXa serially during hospitalization to determine consistent activity within the target range and whether such fluctuations reflected changes in disease severity or outcomes. One of four patients, not an insignificant proportion, required dose adjustment and six of 11 patients experienced a bleeding or confirmed/suspected thrombotic event. The corresponding anti-FXa measured ahead or at the time of these events is not provided. Bleeding complications in patients with COVID-19 are reported in the literature and, in addition to thrombotic outcomes, represent important endpoints for ongoing randomized controlled clinical trials.Since the start of the COVID-19 pandemic, despite an evolution in anticoagulation regimes for the prevention of thrombotic complications based mainly on retrospective data, we believe the relationship between patient-specific factors for thrombosis and hemorrhage and anti-FXa concentrations remain an important consideration. Until we understand further the discordance of the anti-FXa in COVID-19, its relevance, and the targets one should aim for to achieve safe and effective hemostasis, we would urge caution against disregarding anti-FXa activity as a potential tool in a patient group with a high risk of thrombosis and bleeding while receiving anticoagulation. n